Prognostic role of microRNA-126 for survival in malignant tumors: A systematic review and meta-analysis

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Bu, Jie ^a   Li, Hui ^a   Li, Xiao Yang ^a   Liu, Li Hong ^a   Sun, Wei ^a   Xiao, Tao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 126; MICRORNA; MIRN126 MICRORNA, HUMAN; TUMOR MARKER;

CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA; CNKI DATABASE; COCHRANE LIBRARY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; EMBASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL PREDICTION; SYSTEMATIC REVIEW; WANFANG DATABASE; GENETICS; META ANALYSIS; NEOPLASM; PATHOLOGY;

BIOMARKERS, TUMOR; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84940876954     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/739469     Document Type: Review

References (78)

1. J. Lu, G. Getz, E. A. Miska et al., "MicroRNA expression profiles classify human cancers," Nature, vol. 435, no. 7043, pp. 834-838, 2005.
2. Y. Suarez and W. C. Sessa, "MicroRNAs as novel regulators of angiogenesis," Circulation Research, vol. 104, no. 4, pp. 442-454, 2009.
3. R. Garzon, M. Fabbri, A. Cimmino, G. A. Calin, and C. M. Croce, "MicroRNA expression and function in cancer," Trends in Molecular Medicine, vol. 12, no. 12, pp. 580-587, 2006.
4. Z. Li and T. M. Rana, "Therapeutic targeting of microRNAs: current status and future challenges," Nature Reviews Drug Discovery, vol. 13, no. 8, pp. 622-638, 2014.
5. L. P. Lim, N. C. Lau, P. Garrett-Engele et al., "Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs," Nature, vol. 433, no. 7027, pp. 769-773, 2005.
6. V. Ambros, "The functions of animal microRNAs," Nature, vol. 431, no. 7006, pp. 350-355, 2004.
7. M. Ferracin, A. Veronese, and M. Negrini, "Micromarkers: miRNAs in cancer diagnosis and prognosis," Expert Review of Molecular Diagnostics, vol. 10, no. 3, pp. 297-308, 2010.
8. J. E. Fish, M. M. Santoro, S. U. Morton et al., "miR-126 regulates angiogenic signaling and vascular integrity," Developmental Cell, vol. 15, no. 2, pp. 272-284, 2008.
9. J. Meister and M. H. H. Schmidt, "miR-126 and miR-126∗: newplayers in cancer,"TheScientificWorldJOURNAL, vol. 10, pp. 2090-2100, 2010.
10. S. Wang, A. B. Aurora, B. A. Johnson et al., "The endothelialspecific microRNA miR-126 governs vascular integrity and angiogenesis," Developmental Cell, vol. 15, no. 2, pp. 261-271, 2008.
11. T. A. Harris, M. Yamakuchi, M. Ferlito, J. T. Mendell, and C. J. Lowenstein, "MicroRNA-126 regulates endothelial expression of vascular cell adhesionmolecule 1," Proceedings of theNational Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1516-1521, 2008.
12. Y. Zhou, X. Feng, Y.-L. Liuet al., "Down-regulationofmiR-126is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways," PLoS ONE, vol. 8, no. 11, Article ID e81203, 2013.
13. B. Liu, X.-C. Peng, X.-L. Zheng, J. Wang, and Y.-W. Qin, "MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo, Lung Cancer, vol. 66, no. 2, pp. 169-175, 2009.
14. S. F. Tavazoie, C. Alarcon, T. Oskarsson et al., "Endogenous human microRNAs that suppress breast cancer metastasis," Nature, vol. 451, no. 7175, pp. 147-152, 2008.
15. R. Feng, X. Chen, Y. Yu et al., "miR-126 functions as a tumour suppressor in human gastric cancer," Cancer Letters, vol. 298, no. 1, pp. 50-63, 2010.
16. Z. Li, N. Li, M. Wu, X. Li, Z. Luo, and X. Wang, "Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4,"Molecular and Cellular Biochemistry, vol. 381, no. 1-2, pp. 233-242, 2013.
17. L. R. Jiao, A. E. Frampton, J. Jacob et al., "Micrornas targeting oncogenes are down-regulated in pancreatic malignant transformation frombenign tumors," PLoS ONE, vol. 7, no. 2, Article ID e32068, 2012.
18. X. Yang, H. Wu, and T. Ling, "Suppressive effect of microRNA-126 on oral squamous cell carcinoma in vitro," Molecular Medicine Reports, vol. 10, no. 1, pp. 125-130, 2014.
19. T. Otsubo, Y. Akiyama, Y. Hashimoto, S. Shimada, K. Goto, and Y. Yuasa, "Microrna-126 inhibits SOX2 expression and contributes to gastric carcinogenesis," PLoS ONE, vol. 6, no. 1, Article ID e16617, 2011.
20. I. Barshack, E. Meiri, S. Rosenwald et al., "Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression," International Journal of Biochemistry and Cell Biology, vol. 42, no. 8, pp. 1355-1362, 2010.
21. Z. Li and J. Chen, "In vitro functional study of miR-126 in leukemia," Methods in Molecular Biology, vol. 676, pp. 185-195, 2011.
22. W.-F. Shen, Y.-L. Hu, L. Uttarwar, E. Passegue, and C. Largman, "microRNA-126 regulates HOXA9 by binding to the homeobox," Molecular and Cellular Biology, vol. 28, no. 14, pp. 4609-4619, 2008.
23. M. V. Iorio and C. M. Croce, "MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. Acomprehensive review," EMBO Molecular Medicine, vol. 4, no. 3, pp. 143-159, 2012.
24. F. Ebrahimi, V. Gopalan, R. A. Smith, and A. K. Lam, "miR-126 in human cancers: clinical roles and current perspectives," Experimental and Molecular Pathology, vol. 96, no. 1, pp. 98-107, 2014.
25. D. F. Stroup, J. A. Berlin, S. C. Morton et al., "Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group," The Journal of the American Medical Association, vol. 283, no. 15, pp. 2008-2012, 2000.
26. Y. Shao, Y. Geng, W. Gu, J. Huang, H. Pei, and J. Jiang, "Prognostic role of tissue and circulating microRNA-200c in malignant tumors: a systematic review and meta-analysis," Cellular Physiology and Biochemistry, vol. 35, no. 3, pp. 1188-1200, 2015.
27. Z. Zhang, T. Wang, J. Zhang et al., "Prognostic value of epidermal growth factor receptor mutations in resected nonsmall cell lung cancer: a systematic review with meta-analysis," PLoS ONE, vol. 9, no. 8, Article ID e106053, 2014.
28. J. F. Tierney, L. A. Stewart, D. Ghersi, S. Burdett, and M. R. Sydes, "Practical methods for incorporating summary time-toevent data into meta-analysis," Trials, vol. 8, article 16, 2007.
29. M. K. B. Parmar, V. Torri, and L. Stewart, "Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints," Statistics in Medicine, vol. 17, no. 24, pp. 2815-2834, 1998.
30. J. Lau, J. P. A. Ioannidis, and C. H. Schmid, "Quantitative synthesis in systematic reviews," Annals of Internal Medicine, vol. 127, no. 9, pp. 820-826, 1997.
31. J. P. Higgins and S. G. Thompson, "Quantifying heterogeneity in a meta-analysis," Statistics in Medicine, vol. 21, no. 11, pp. 1539-1558, 2002.
32. R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," Controlled Clinical Trials, vol. 7, no. 3, pp. 177-188, 1986.
33. N. Mantel and W. Haenszel, "Statistical aspects of the analysis of data from retrospective studies of disease," Journal of the National Cancer Institute, vol. 22, no. 4, pp. 719-748, 1959.
34. C. B. Begg and M. Mazumdar, "Operating characteristics of a rank correlation test for publication bias," Biometrics, vol. 50, no. 4, pp. 1088-1101, 1994.
35. M. Egger, G. D. Smith, M. Schneider, and C. Minder, "Bias in meta-analysis detected by a simple, graphical test," British Medical Journal, vol. 315, no. 7109, pp. 629-634, 1997.
36. Y. Shibayama, T. Kondo, H. Ohya, S. Fujisawa, T. Teshima, and K. Iseki, "Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients," Oncology Reports, vol. 33, no. 5, pp. 2176-2182, 2015.
37. K. Ishihara, D. Sasaki, K. Tsuruda et al., "Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia," Cancer Epidemiology, vol. 36, no. 6, pp. 560-565, 2012.
38. D. C. de Leeuw, F. Denkers, M. C. Olthof et al., "Attenuation of microRNA-126 expression that drives CD34+38-stem/progenitor cells in acute myeloid leukemia leads to tumor eradication," Cancer Research, vol. 74, no. 7, pp. 2094-2105, 2014.
39. C. Sanfiorenzo, M. I. Ilie, A. Belaid et al., "Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC," PLoS ONE, vol. 8, no. 1, Article ID e54596, 2013.
40. T. Donnem, K. Lonvik, K. Eklo et al., "Independent and tissuespecific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factora predicts poor surviva," Cancer, vol. 117, no. 14, pp. 3193-3200, 2011.
41. M. K. Kim, S. B. Jung, J.-S. Kimet al., "Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer," Virchows Archiv, vol. 465, no. 4, pp. 463-471, 2014.
42. E. Jusufovic, M. Rijavec, D. Keser et al., "Let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer," PLoS ONE, vol. 7, no. 9, Article ID e45577, 2012.
43. J. Yang, H. Lan, X. Huang, B. Liu, and Y. Tong, "MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients," PLoS ONE, vol. 7, no. 8, Article ID e42978, 2012.
44. X. Li, G. Wan, Y. Liang, C. Sun, and H. Dong, "Effect ofmiR-126 on cell cycle regulation and prognosis of lung cancer patients," Journal of Practical Oncology, vol. 29, no. 5, pp. 440-445, 2014.
45. Z. B. Han, L. Zhong, M. J. Teng et al., "Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation," Molecular Oncology, vol. 6, no. 4, pp. 445-457, 2012.
46. H. Chen, R. Miao, J. Fan et al., "Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma," Clinical and Experimental Metastasis, vol. 30, no. 5, pp. 651-658, 2013.
47. Y. Yang, K. L. Song, H. Chang, and L. Chen, "Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer," Diagnostic Pathology, vol. 9, no. 1, article 220, 2014.
48. X. Sun, Z.-M. Wang, Y. Song, X. U.-H. Tai, W.-Y. Ji, and H. Gu, "MicroRNA-126 modulates the tumor microenvironment by targeting calmodulin-regulated spectrin-associated protein (Camsap1)," International Journal of Oncology, vol. 44, no. 5, pp. 1678-1684, 2014.
49. T. F. Hansen, F. B. Sorensen, J. Lindebjerg, and A. Jakobsen, "The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer," BMC Cancer, vol. 12, article 83, 2012.
50. T. F. Hansen, S. Kjr-Frifeldt, S. Morgenthaler et al., "The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort," Journal of TranslationalMedicine, vol. 12, no. 1, article 254, 2014.
51. N. Li, X. Li, S. Huang, S. Shen, and X. Wang, "miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene," Zhong Nan Da Xue Xue Bao Yi Xue Ban, vol. 38, no. 8, pp. 809-817, 2013.
52. Y. Liu, Y. Zhou, X. Feng et al., "Low expression of MicroRNA-126 is associated with poor prognosis in colorectal cancer," Genes Chromosomes and Cancer, vol. 53, no. 4, pp. 358-365, 2014.
53. R. Diaz, J. Silva, J. M. Garcia et al., "Deregulated expression of miR-106a predicts survival in human colon cancer patients," Genes, Chromosomes and Cancer, vol. 47, no. 9, pp. 794-802, 2008.
54. T. F. Hansen, C. L. Andersen, B. S. Nielsen et al., "Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer," Oncology Letters, vol. 2, no. 6, pp. 1101-1106, 2011.
55. T. F. Hansen, R. D. P. Christensen, R. F. Andersen, F. B. Sorensen, A. Johnsson, and A. Jakobsen, "MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial," British Journal of Cancer, vol. 109, no. 5, pp. 1243-1251, 2013.
56. T. F. Hansen, A. L. Carlsen, N. H. H. Heegaard, F. B. Sorensen, andA. Jakobsen, "Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer," British Journal of Cancer, vol. 112, no. 4, pp. 624-629, 2015.
57. T. Sasahira, M. Kurihara, U. K. Bhawal et al., "Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer," British Journal of Cancer, vol. 107, no. 4, pp. 700-706, 2012.
58. X. Sun, Z. Liu, Z. Yang et al., "Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy," Diagnostic Pathology, vol. 8, article 208, 2013.
59. R. Hoppe, J. Achinger-Kawecka, S. Winter et al., "Increased expression of miR-126 and miR-10a predict prolonged relapsefree time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment," European Journal of Cancer, vol. 49, no. 17, pp. 3598-3608, 2013.
60. D. C. Vergho, S. Kneitz, C. Kalogirou et al., "Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava," PLoS ONE, vol. 9, no. 10, Article IDe109877, 2014.
61. H. W. Khella, A. Scorilas, R. Mozes et al., "Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma," The American Journal of Pathology, vol. 185, no. 3, pp. 693-703, 2015.
62. R. Liu, J. Gu, P. Jiang et al., "DNMT1-microrna126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth viaADAM9-EGFR-akt signaling," Clinical Cancer Research, vol. 21, no. 4, pp. 854-863, 2015.
63. Y. Hu, A. M. Correa, A. Hoque et al., "Prognostic significance of differentially expressed miRNAs in esophageal cancer," International Journal of Cancer, vol. 128, no. 1, pp. 132-143, 2011.
64. J. Wang, Z. Ling, and W. Mao, "Expressions and clinical significances of microRNA-126 and microRNA-7 in esophageal squmous cell carcinoma," Journal of International Oncology, vol. 40, no. 12, pp. 936-940, 2013.
65. J. Feng, S.-T. Kim, W. Liu et al., "An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21. 3 in glioblastoma," Cancer, vol. 118, no. 1, pp. 232-240, 2012.
66. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012," CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87-108, 2015.
67. D. Paul, A. Kumar, A. Gajbhiye, M. K. Santra, and R. Srikanth, "Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture," BioMed Research International, vol. 2013, Article ID 783131, 16 pages, 2013.
68. C. A. Gonzalez and A. Agudo, "Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go," International Journal of Cancer, vol. 130, no. 4, pp. 745-753, 2012.
69. Y.-Q. Sun, F. Zhang, Y.-F. Bai, and L.-L. Guo, "miR-126 modulates the expression of epidermal growth factor-like domain 7 in human umbilical vein endothelial cells in vitro," Nan Fang Yi Ke Da Xue Xue Bao, vol. 30, no. 4, pp. 767-770, 2010.
70. K. J. Png, N. Halberg, M. Yoshida, and S. F. Tavazoie, "A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells," Nature, vol. 481, no. 7380, pp. 190-194, 2012.
71. N. Zhu, D. Zhang, H. Xie et al., "Endothelial-specific intronderived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2," Molecular and Cellular Biochemistry, vol. 351, no. 1-2, pp. 157-164, 2011.
72. C. Du, Z. Lv, L. Cao et al., "MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2," Journal of TranslationalMedicine, vol. 12, article 259, 2014.
73. S. Hamada, K. Satoh, W. Fujibuchi et al., "MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9," Molecular Cancer Research, vol. 10, no. 1, pp. 3-10, 2012.
74. K. E. Resnick, H. Alder, J. P. Hagan, D. L. Richardson, C. M. Croce, and D. E. Cohn, "The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform," Gynecologic Oncology, vol. 112, no. 1, pp. 55-59, 2009.
75. G. Cammarata, L. Augugliaro, D. Salemi et al., "Differential expression of specific microRNA and their targets in acute myeloid leukemia," American Journal ofHematology, vol. 85, no. 5, pp. 331-339, 2010.
76. Z. Li, J. Lu, M. Sun et al., "Distinct microRNA expression profiles in acute myeloid leukemia with common translocations," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 40, pp. 15535-15540, 2008.
77. T. Donnem, C. G. Fenton, K. Lonvik et al., "MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer," PLoSONE, vol. 7, no. 1, Article IDe29671, 2012.
78. A. Watahiki, Y. Wang, J. Morris et al., "MicroRNAs associated withmetastatic prostate cancer," PLoS ONE, vol. 6, no. 9, Article ID e24950, 2011.